Skip to main content
ASCO 2023 Highlights
Inetetamab Plus Camrelizumab and Utidelone Safe and Effective in Patients With HER2-Positive Metastatic Breast Cancer
Read More
ASCO 2023 Highlights
Dalpiciclib Plus Pyrotinib Prolongs Survival in Patients With HER2-Positive Advanced Breast Cancer
Read More
ASCO 2023 Highlights
Neratinib Plus Trastuzumab Emtansine in Patients With HER2-Positive Breast Cancer and Molecular Residual Disease
Read More
ASCO 2023 Highlights
Anti-HER2/HER3 αDC1 Vaccines Plus Pembrolizumab for Brain Metastases in Patients With Triple-Negative or HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Strong Antitumor Activity With Neoadjuvant Intratumoral Dendritic Cell Vaccine Therapy Plus Paclitaxel, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Phase 1b/2 Trial of Ribociclib, Tucatinib, and Trastuzumab to Find Chemotherapy-Free Treatment Combination Regimens for HER2-Positive Breast Cancer
Read More
ASCO 2023 Highlights
Dalpiciclib Plus Pyrotinib and Endocrine Therapy Shows Promising Antitumor Activity in ER-Positive, HER2-Positive Metastatic Breast Cancer
Read More
ASCO 2023 Highlights
Preclinical and Early Clinical Data Show Promising Antitumor Activity With the HER2 Inhibitor ZN-1041 in Patients With Breast Cancer and Brain Metastases
Read More
FDA Updates
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
Read More
FDA Updates
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
Read More
Page 33 of 197
Results 321 - 330 of 1963